These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 31580408)

  • 1. Current targeted therapies in lymphomas.
    Chung C
    Am J Health Syst Pharm; 2019 Oct; 76(22):1825-1834. PubMed ID: 31580408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
    Bhatt G; Maddocks K; Christian B
    Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
    Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
    Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
    Makita S; Hosoba R; Tobinai K
    Expert Opin Drug Saf; 2020 Sep; 19(9):1105-1120. PubMed ID: 32715803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lymphomas: A therapeutic update].
    Wolfromm A; Delarue R
    Rev Med Interne; 2017 Oct; 38(10):685-690. PubMed ID: 28958786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakthrough therapies in B-cell non-Hodgkin lymphoma.
    Cheah CY; Fowler NH; Wang ML
    Ann Oncol; 2016 May; 27(5):778-87. PubMed ID: 26802148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Pierce JM; Mehta A
    Expert Rev Hematol; 2017 Jan; 10(1):29-37. PubMed ID: 27927047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.
    Deshpande A; Munoz J
    Front Oncol; 2022; 12():948513. PubMed ID: 36172151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
    Watkins MP; Bartlett NL
    Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
    Kasenda B; Kühnl A; Chau I
    Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
    Broccoli A; Argnani L; Zinzani PL
    Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug therapy of lymphomas].
    Gergely L
    Magy Onkol; 2017 Mar; 61(1):89-96. PubMed ID: 28273193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapies for lymphoma.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA; Foon KA
    Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for lymphomas.
    Timmerman JM
    Int J Hematol; 2003 Jun; 77(5):444-55. PubMed ID: 12841382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
    Lykken JM; Tedder TF
    Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.